Kalbe Farma Tbk PT (KLBF.JK)

KLBF.JK on Jakarta Stock Exchange

1,800.00IDR
19 Dec 2014
Price Change (% chg)

Rp. 25.00 (+1.41%)
Prev Close
Rp. 1,775.00
Open
Rp. 1,785.00
Day's High
Rp. 1,800.00
Day's Low
Rp. 1,760.00
Volume
42,321,500
Avg. Vol
38,308,891
52-wk High
Rp. 1,835.00
52-wk Low
Rp. 1,180.00

KLBF.JK

Chart for KLBF.JK

About

PT Kalbe Farma Tbk is an Indonesia-based pharmaceutical company. It has four core business segments, namely prescription pharmaceutical, consumer health, nutritionals, and distribution. Under the prescription pharmaceuticals division, the Company is engaged in the development, production and distribution of pharmaceutical... (more)

Overall

Beta: 0.92
Market Cap (Mil.): Rp. 84,375,216.00
Shares Outstanding (Mil.): 46,875.12
Dividend: 17.00
Yield (%): 0.94

Financials

  KLBF.JK Industry Sector
P/E (TTM): 41.36 37.83 38.47
EPS (TTM): 43.52 -- --
ROI: 25.08 18.99 18.25
ROE: 24.94 19.75 19.13
Search Stocks

INDONESIA PRESS-Kalbe Farma plans capex of up to 1.5 trln rph for 2015 -Kontan

PT Kalbe Farma, Indonesia's largest pharmaceutical company, plans a capital expenditure of between 1 trillion rupiah ($82.41 million) and 1.5 trillion rupiah in 2015, up from this year's target of between 1 trillion rupiah and 1.2 trillion rupiah, said Corporate Secretary Vidjongtius.

09 Nov 2014

INDONESIA PRESS-Kalbe Farma eyes shares in Pharos-Investor Daily

PT Kalbe Farma Tbk, Indonesia's largest pharmaceutical company, is interested in buying shares of PT Pharos, the pharmaceutical unit of conglomerate Rajawali Nusantara Indonesia, during its initial public offering scheduled for early 2015, said Kalbe Director Vidjongtius.

11 Aug 2014

INDONESIA PRESS-Kalbe Farma cuts 2014 sales growth target-Bisnis Indonesia

PT Kalbe Farma Tbk, Indonesia's largest pharmaceutical company, cut its 2014 sales growth target to 11-13 percent from 14-16 percent after sales in four divisions, including prescription drugs and nutritional products, slowed in the first half this year, said Finance Director Vidjongtius. (Bisnis Indonesia)

10 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00
Provider: Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks